Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Travere Therapeutics, Inc.TVTX · Entity 1562 | SVP, CHIEF ACCOUNTING OFFICER | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Travere Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,353 |
Ending reported balance
After 2026-09-15 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 2,500 · Balance 44,853 Row 2 · 2026-09-15 · Exercise / conversion · Acquired 1,250 · Balance 46,103 Row 3 · 2026-09-15 · Exercise / conversion · Acquired 1,625 · Balance 47,728 Row 4 · 2026-09-15 · Sale · Disposed 4,275 · Balance 43,453 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2: The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-09-15 · Sale · Disposed 800 · Balance 42,653 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3: The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 6 · 2026-09-15 · Sale · Disposed 300 · Balance 42,353 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4: The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.50 · Expires 2032-01-31 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 2,500 · Balance 0 F5: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.40 · Expires 2033-01-31 | Direct | 3,750 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 1,250 · Balance 3,750 F6: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.46 · Expires 2035-01-31 | Direct | 17,875 |
Reported balance
After 2026-09-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-15 · Exercise / conversion · Disposed 1,625 · Balance 17,875 F7: One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2: The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The stock option is fully vested and exercisable.
F6: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
F7: One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2024 Filed Dec 28, 2024 00:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 15,000 | $17.22 | $258,277.50 |
DisclosureSEC source: 0001415889-24-030210 · form4-12282024_121201.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,927 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, adopted by the Reporting Person on September 9, 2024. F2 · price: The weighted average sale price for the transaction reported was $17.21856, and the range of prices were between $16.985 and $17.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| December 26, 2024 Filed Dec 28, 2024 00:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 15,000 | $12.67 | $190,050.00 |
DisclosureSEC source: 0001415889-24-030210 · form4-12282024_121201.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 02:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.67 | $0.00 |
DisclosureSEC source: 0001415889-24-027672 · form4-11262024_021145.xml · derivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 02:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 12,090 | $18.30 | $221,257.88 |
DisclosureSEC source: 0001415889-24-027672 · form4-11262024_021145.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,927 F1 · shares: Represents the number of shares required to be sold by the Reporting Person in order to cover the tax withholding obligation and payment of the exercise price in connection with the partial exercise of a stock option granted to the Reporting Person on January 2, 2015 with an upcoming expiration date of January 2, 2025. F2 · price: The weighted average sale price for the transaction reported was $18.3009, and the range of prices were between $18.27 and $18.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 02:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 15,000 | $12.67 | $190,050.00 |
DisclosureSEC source: 0001415889-24-027672 · form4-11262024_021145.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,820 | $8.53 | $24,057.98 |
DisclosureSEC source: 0001415889-24-002279 · form4-02022024_040202.xml · nonDerivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,017 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F3 · price: The weighted average sale price for the reported transaction was $8.5312, and the range of prices were between $8.5309 and $8.5315. Upon request by the SEC staff, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001415889-24-002279 · form4-02022024_040202.xml · derivative · entry 4 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-01-30 F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002279 · form4-02022024_040202.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,837 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002279 · form4-02022024_040202.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,837 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:10 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 910 | $9.07 | $8,252.24 |
DisclosureSEC source: 0001415889-24-001796 · form4-01252024_040102.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,337 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:06 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 122 | $16.12 | $1,966.64 |
DisclosureSEC source: 0001209191-23-028993 · doc4.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,247 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on September 14, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:06 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 436 | $16.59 | $7,233.24 |
DisclosureSEC source: 0001209191-23-028993 · doc4.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,369 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 02, 2023 Filed Feb 2, 2023 23:53 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 360 | $22.42 | $8,071.20 |
DisclosureSEC source: 0001209191-23-006413 · doc4.xml · nonDerivative · entry 3 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,805 F3 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 23:53 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,671 | $21.75 | $36,347.59 |
DisclosureSEC source: 0001209191-23-006413 · doc4.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,165 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 23:53 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001209191-23-006413 · doc4.xml · derivative · entry 4 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-30 F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 23:53 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006413 · doc4.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,836 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 192 | $21.63 | $4,152.96 |
DisclosureSEC source: 0001209191-23-005037 · doc4.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,836 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 905 | $21.90 | $19,823.48 |
DisclosureSEC source: 0001209191-23-005037 · doc4.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,028 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 349 | $28.00 | $9,772.00 |
DisclosureSEC source: 0001209191-22-050038 · doc4.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,933 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 549 shares of the Issuer's common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:44 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 445 | $21.92 | $9,755.96 |
DisclosureSEC source: 0001209191-22-028706 · doc4.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,733 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:44 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 436 | $21.51 | $9,378.36 |
DisclosureSEC source: 0001209191-22-028706 · doc4.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,178 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:22 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 17,500 | $0.00 Strike: $27.50 | $0.00 |
DisclosureSEC source: 0001209191-22-006372 · doc4.xml · derivative · entry 3 Calvin Sandra · CIK 0001882909 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-01-30 F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:22 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 798 | $26.51 | $21,151.71 |
DisclosureSEC source: 0001209191-22-006372 · doc4.xml · nonDerivative · entry 2 Calvin Sandra · CIK 0001882909 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,614 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:22 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006372 · doc4.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,412 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:38 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 934 | $24.58 | $22,954.64 |
DisclosureSEC source: 0001209191-22-005084 · doc4.xml · nonDerivative · entry 1 Calvin Sandra · CIK 0001882909 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,662 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 842 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.